Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

115.87 -0.83 (-0.71%)
Streaming Delayed Price Updated: 11:05 AM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production. 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Smartest Vanguard ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years
This company stands to benefit from the advances in artificial intelligence more than any other business. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings Scheduled For April 29, 2025
Via Benzinga
Earnings Preview For Novartis
Via Benzinga
Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks
IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors. 
Via Benzinga
Topics ETFs
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
Here's My Favorite High-Dividend ETF to Buy Right Now
Via The Motley Fool
Topics ETFs
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting. 
Via Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
Exposures Product Safety
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion. 
Via Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
Exposures US Equities
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership. 
Via Benzinga
Topics Earnings
Exposures Financial
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025. 
Via Benzinga
AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition
Edgewater noted that the mobile gaming macro environment appears to be decelerating gradually, while competition from both Meta and Alphabet is intensifying. 
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis
According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million. 
Via Stocktwits
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales. 
Via Benzinga
Topics Earnings
Exposures Financial
Novartis Creeps Toward A Breakout On Its Beat-And-Raise
Shares are consolidating and are now trading above their 50-day and 200-day lines. 
Via Investor's Business Daily
Exposures Product Safety
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this... 
Via Benzinga
General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion. 
Via MarketBeat
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Political
The Smartest International Stock ETF to Buy With $100 Right Now
It could be time for international stocks to shine, making this ETF a must-own. 
Via The Motley Fool
Topics ETFs Economy
Exposures Economy
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Via The Motley Fool
Topics Economy Government Lawsuit
Exposures Financial Interest Rates Legal
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NOVARTIS AG-SPONSORED ADR has a stellar value proposition. NYSE:NVS not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
S&P 500, Nasdaq Futures Rise After Stocks Dip Amid Trump's Jabs At Powell, Strong Yen Gives Nikkei A Volatile Start
U.S. stock futures rose Monday night even as Wall Street had a rough start to the week, amid growing concerns regarding the Federal Reserve's independence, and President Donald Trump's repeated attacks... 
Via Benzinga
Topics Economy Government Stocks
Exposures Interest Rates Political US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.